Shoppers Drug Mart Corp (SC.TO)

PAST TOP PICK
(A Top Pick Jan 5/09. Down 3.59%.) This has been a disappointment. Has had really good earnings and have done all the right things in terms of renewing their stores and opening new real estate but hasn't had any respect from the market. Really cheap and still a buy.
BUY
Big risk is a cap on prices. It has held back the price. But it is a play on demographics. There is no competition. They had a great year and the stock is down. Free cash flow will grow significantly and company could raise dividend. The risk is fully priced in. The stock looks cheap.
PAST TOP PICK
(A Top Pick May 5/09.) Doesn't own since he is managing a new fund. Still likes.
BUY ON WEAKNESS
Fixed a lot of operations so profitability continued to go up. Then reached the zenith and continued at a premium price is if the improvement profitability was going to continue. Rebates on generic drug products are falling and have to be made up on the front end of the store. Would like to see the price below $40.
TOP PICK
A bit of a cloud because of changes coming in Ontario legislation, which probably won't be until spring. Best drugstore company in North America. A way of playing aging population, increasing demand for drugs in a company that has high and growing margins. Still has great potential for adding square footage in new stores.
BUY
Likes this one long-term. Traffic has been weaker generally for all retailers because of the recession. Likes the demographics of the aging population. Well organized merchandise front end in their stores. Good, long-term Buy.
TOP PICK
A bit of an overhang right now because of the Ontario government's drug reform. Expects a significant increase in free cash flow over the next several years. 1.97% yield.
PAST TOP PICK
(A Top Pick May 5/09. No change.) A dead stock now waiting for the Ontario government to make a decision.
PAST TOP PICK
(A Top Pick Jan 27/09. Up 9.5%.) January/12 @ 4.8%. Recently trimmed art of his position.
WATCH
Lower quality, more cyclical stocks have been leading the market as opposed to consumer/non-discretionary have lagged. Also Ontario government are looking at their reimbursement policy for pharmacies. Looking at this one and may invest in it in the near future.
DON'T BUY
A market neutral play. Earnings coming out next week and he expects them to be reasonably good. Same-store sales are good but not sure they can continue at the same pace.
BUY ON WEAKNESS
Looking at this one very carefully. A bit sceptical on the damage by the new Ontario legislation. Would prefer it at $40.
PAST TOP PICK
(A Top Pick May 14/09. Down 1.7%.) Historically the pharmaceutical side is very profitable but the Ontario regulatory review is making investors nervous.
WATCH
Runs a great operation. Some doubt has crept in to some people’s minds. Noises from provincial government about cutting back margins. This Christmas will be a good test of their new strategies.
BUY
Stock went down after 2nd quarter earnings. Market was a little distraught at their forecast for growth but latest earnings were pretty good. Same-store sales were up sharply. Concern about cutting back on prescription reimbursements had an overreaction.
Showing 151 to 165 of 452 entries